about
H7N9 Live Attenuated Influenza Vaccine Is Highly Immunogenic, Prevents Virus Replication, and Protects Against Severe Bronchopneumonia in Ferrets.Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets.Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries.Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers.Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.Will there ever be a new influenza pandemic and are we prepared?Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses.H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial.Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.Phenotypic characteristics of novel swine-origin influenza A/California/07/2009 (H1N1) virusComparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium.Possible outcomes of reassortment in vivo between wild type and live attenuated influenza vaccine strains.Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials).Development of one-step real-time PCR assay for titrating trivalent live attenuated influenza vaccines.Implementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses.Immunization with live influenza viruses in an experimental model of allergic bronchial asthma: infection and vaccinationMemory T-cell immune response in healthy young adults vaccinated with live attenuated influenza A (H5N2) vaccine.Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers.Interferon and other proinflamatory cytokine responses in vitro following infection with wild-type and cold-adapted reassortant influenza viruses.Phenotypic and genetic analyses of the heterogeneous population present in the cold-adapted master donor strain: A/Leningrad/134/17/57 (H2N2).Cell-based assay for the determination of temperature sensitive and cold adapted phenotypes of influenza viruses.Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine.Comparative safety, immunogenicity, and efficacy of several anti-H5N1 influenza experimental vaccines in a mouse and chicken models (Testing of killed and live H5 vaccine).B- and T-cell memory elicited by a seasonal live attenuated reassortant influenza vaccine: assessment of local antibody avidity and virus-specific memory T-cells using trogocytosis-based method.Contribution of neuraminidase of influenza viruses to the sensitivity to sera inhibitors and reassortment efficiencyH7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus.Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2).Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia.Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets.Comparative studies of local antibody and cellular immune responses to influenza infection and vaccination with live attenuated reassortant influenza vaccine (LAIV) utilizing a mouse nasal-associated lymphoid tissue (NALT) separation method.Reassortant viruses for influenza vaccines: is it time to reconsider their genome structures?Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.H7N9: can H7N3 live-attenuated influenza vaccine be used at the early stage of the pandemic?
P50
Q30196901-0CC68FF5-0426-4363-B902-34F874E9BDA6Q30205252-DE707354-E5F2-4832-AFD4-36C05143069BQ30224970-567F195A-A6EC-4E78-83E3-B5FBCC6700C9Q30226518-746F7764-822C-4219-A033-5F20476A958AQ30357308-883F15BE-5B4B-4B2A-B260-CCF31EF34870Q30359013-C36289C9-4434-44AB-A937-23B12A7EC25EQ30360436-660F8856-57A6-457D-B671-38027C60A3BEQ30365079-8C2FD9A8-47BB-4A9F-AE90-AA190351616AQ30373298-12DC970A-1286-4757-BC15-F937C1241A8AQ30373917-AF898F77-651B-427F-B581-E9C8241ACAB7Q30378132-C797F427-1D5F-4932-A403-1188E833FA2AQ30378200-F1098C14-CBE6-4E8C-BBBA-B35A8BAEDD27Q30379648-D3959D76-F451-4F19-9F63-3EDA72495C97Q30379886-EC2BF019-BDD1-4E75-B00B-2FF5221EDC64Q30382548-2D84C9F8-4954-4F5B-B39A-DCC1B99BABC5Q30382809-0FDC7470-5A97-46A6-A51D-2A70668A99F6Q30383629-F6CA7CAB-7AD4-4A36-920E-408DC7398F0EQ30420603-64D95BAF-788F-4ED2-B5EB-91895BA2B0CEQ30422329-F163389F-6B6C-4E98-B362-E6C60435430DQ33447721-61A434C6-77FE-4D03-9A71-82DC965518C8Q35886506-D6EB1E8F-5126-4571-8C3A-FDBB7D8790F9Q36637886-5227FAAD-2442-4EE8-8618-A345811FF624Q37087674-B86378F0-09F9-4540-B01F-716339B5C11AQ38627438-EE14E42A-8F9F-4E23-A6F7-E20150933E74Q38991947-911DBF36-3069-4089-A71E-1DFA2EA97E71Q40253159-FCBD44BC-A7B0-4EA6-AF7F-0E96296E7D1EQ40566885-96507110-5D70-4415-B08D-AAB21023ADFFQ40600675-787255A2-2688-4470-B03C-4827FD123B12Q41635120-64F136C6-BE4D-463F-BF1E-01CBAA8273CFQ41898855-BC2A13B9-CEE8-4BE1-8FFB-30A9F065C37DQ42115724-186F0292-312A-4D24-9DDB-2F7C58AEF936Q42199354-BB0B7A9F-64B5-4D47-8E9C-965F63CE6E9AQ42273410-E87D72EC-538D-43F6-BECB-76E6AB3F98C0Q43173226-E66A3762-A6D5-40EE-BE87-B0804C97D482Q43208959-28B69314-A544-4285-9A9B-D43BD2DFD381Q44943273-05606DDC-10E0-4AB3-AB5C-0E3790BFDECCQ47841089-9BD4D8F9-A719-4531-BDAD-AAF4F2568669Q50890564-AF04FF3C-6BED-4678-877B-768ADE0AA1CEQ50950154-5A251254-1D17-4373-BB6D-F04207FFA1ADQ51856923-DA815C2F-D684-463D-B73C-5323A8FD539A
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Larisa Rudenko
@ast
Larisa Rudenko
@en
Larisa Rudenko
@es
Larisa Rudenko
@nl
Larisa Rudenko
@sl
type
label
Larisa Rudenko
@ast
Larisa Rudenko
@en
Larisa Rudenko
@es
Larisa Rudenko
@nl
Larisa Rudenko
@sl
altLabel
Rudenko Larisa G
@en
prefLabel
Larisa Rudenko
@ast
Larisa Rudenko
@en
Larisa Rudenko
@es
Larisa Rudenko
@nl
Larisa Rudenko
@sl
P1053
B-5169-2015
P106
P1153
56402849200
7005033248
P21
P31
P3829
P496
0000-0002-0107-9959